News & Events - Page 2 of 19 - Charcot-Marie-Tooth UK

22/12/23

Conference

Charcot Marie Tooth

CMTUK In Person Conference 2024

Pharnext intends to prepare registration and marketing authorizationdossiers for PXT3003, its drug candidate in Charcot-Marie-Tooth diseasetype 1A

20/12/23

Research

Charcot Marie Tooth

Pharnext intends to prepare registration and marketing authorizationdossiers for PXT3003, its drug candidate in Charcot-Marie-Tooth diseasetype 1A

Pharnext reports topline results from the pivotal Phase III clinical trial(PREMIER trial) of PXT3003 in Charcot-Marie-Tooth disease type 1A

20/12/23

Research

Charcot Marie Tooth

Pharnext reports topline results from the pivotal Phase III clinical trial(PREMIER trial) of PXT3003 in Charcot-Marie-Tooth disease type 1A

30/10/23

Awareness Month

Charcot Marie Tooth

Messages of Support for CMT Awareness Month

Pharnext enters the final stretch for the signature of a licensingagreement for its drug candidate in Charcot-Marie-Tooth disease type 1A(PXT3003), enabling it to capitalize on its assets and put an end to theOCEANE-BSA financing line

20/09/23

Research

Charcot Marie Tooth

Pharnext enters the final stretch for the signature of a licensingagreement for its drug candidate in Charcot-Marie-Tooth disease type 1A(PXT3003), enabling it to capitalize on its assets and put an end to theOCEANE-BSA financing line

19/09/23

Awareness Month

Charcot Marie Tooth

CMT Awareness Month: October 2023

Every year during October, we increase our activities to spread the word as widely as possible throughout the UK about our charity and the condition of Charcot-Marie-Tooth. Please click here to find out what we have planned and how you can get involved.

CMTUK In Person Conference 2024

Pharnext intends to prepare registration and marketing authorizationdossiers for PXT3003, its drug candidate in Charcot-Marie-Tooth diseasetype 1A

Pharnext reports topline results from the pivotal Phase III clinical trial(PREMIER trial) of PXT3003 in Charcot-Marie-Tooth disease type 1A

Messages of Support for CMT Awareness Month

Pharnext enters the final stretch for the signature of a licensingagreement for its drug candidate in Charcot-Marie-Tooth disease type 1A(PXT3003), enabling it to capitalize on its assets and put an end to theOCEANE-BSA financing line

CMT Awareness Month: October 2023

Connect with us

Login